At the Fifth International Consensus Conference for Advanced Breast Cancer, experts agreed that in cases of HR-positive, HER2-negative AMBC in which induction chemotherapy has been effective, endocrine maintenance therapy is a reasonable treatment option [14,15]. The gene discussed is ERBB2; the disease is breast carcinoma.